Skip to main content
Clinical Trials/NCT06093594
NCT06093594
Not yet recruiting
Not Applicable

Understanding Patient Engagement Trends in Stage IV Melanoma Clinical Trials

Power Life Sciences Inc.1 site in 1 country500 target enrollmentNovember 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stage IV Melanoma
Sponsor
Power Life Sciences Inc.
Enrollment
500
Locations
1
Primary Endpoint
Rate of stage IV melanoma patients who remain in clinical trial to trial completion
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.

The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.

Registry
clinicaltrials.gov
Start Date
November 2024
End Date
November 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged ≥ 18 years old
  • Diagnosis of stage IV melanoma
  • Able to comprehend the investigational nature of the protocol and provide informed consent

Exclusion Criteria

  • Female patients who are currently pregnant or nursing
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Inability to perform regular electronic reporting

Outcomes

Primary Outcomes

Rate of stage IV melanoma patients who remain in clinical trial to trial completion

Time Frame: 12 months

Number of stage IV melanoma patients who decide to enroll in a clinical research

Time Frame: 3 months

Study Sites (1)

Loading locations...

Similar Trials